Semaglutide-linked suicidal ideation identified in disproportionality analysis

Semaglutide-associated suicidal ideation has been recognized in a disproportionality evaluation, in keeping with a examine revealed on-line Aug. 20 in JAMA Network Open.

Georgios Schoretsanitis, M.D., Ph.D., from Northwell Health in Glen Oaks, New York, and colleagues examined potential alerts for suicidal and self-injurious adversarial drug reactions (ADRs) related to the glucagon-like peptide 1 receptor agonists semaglutide and liraglutide in a disproportionality evaluation. Participants have been sufferers experiencing an ADR, which was suspected as attributable to semaglutide or liraglutide.

Overall, 107 and 162 circumstances of suicidal and/or self-injurious ADRs have been reported between November 2000 and August 2023 for semaglutide and liraglutide, respectively. The researchers detected important disproportionality for semaglutide-associated suicidal ideation (reporting odds ratio, 1.45), which remained important for these coreporting antidepressant and benzodiazepine use (reporting odds ratios, 4.45 and 4.07, respectively) and in contrast with dapagliflozin, metformin, and orlistat (reporting odds ratios, 5.56, 3.86, and 4.24, respectively).

“We reported a disproportionality sign of suicidal ideation with semaglutide, however not for liraglutide, notably amongst sufferers with coreported antidepressant use, a proxy for affective issues (a notable exclusion standards of premarketing medical trials),” the authors write.

One writer disclosed ties to the biopharmaceutical trade.

© 2024 HealthDay. All rights reserved.